Kornimate/medical-research-clean huggingface dataset:
the use of platelet derived growth factors in total knee arthroplasty, a randomized trial

Conditions: Osteoarthritis

Summary: the objective of this study is to evaluate the effect of autologous platelet concentrate on blood loss (post-operative decrease of haemoglobin concentration), wound healing complications, range of motion, pain reduction and outcome scores when used in total knee arthroplasty.

the short-term functional recovery after a total knee arthroplasty (tka) is largely dependent on initial wound healing. haematoma formation may lead to prolonged wound drainage and tissue necrosis1, which can have a negative effect on early range of motion, post-operative pain and length of hospital stay. in addition, studies have suggested that prolonged wound drainage also leads to a higher infection rate. to decrease haematoma formation, primary soft tissue homeostasis and adequate tissue repair are essential. during the immediate reaction of tissue to injury, haemostasis and inflammation occur. growth factors, especially pdgf (platelet derived growth factor) and tgf-β (transforming growth factor-beta), play a crucial role in the biochemical cascade at the site of repair. these growth factors are mostly derived from platelets. they act as chemotactic agents for polymorphonuclear leucocytes, macrophages, fibroblasts and lymphocytes. both factors stimulate angiogenesis and fibroplasia. pdgf also has a role in wound contraction and remodeling. when applying large concentrations of growth factors in a wound, faster tissue repair and homeostasis can be expected, thus leading to less haematoma formation. treatment with autologous platelet concentrate involves direct application of concentrated platelets, growth factors and fibrin in the operation wound. a small volume (55-110 ml) of the patient's own blood is taken to derive a platelet rich gel which can be sprayed directly into the wound. the objective of this study is to evaluate the effect of autologous platelet concentrate on blood loss (post-operative decrease of haemoglobin concentration), wound healing complications, range of motion, pain reduction and outcome scores when used in total knee arthroplasty.

Eligibility criteria:
inclusion criteria: * patients undergoing primary total knee arthroplasty for primary osteoarthritis exclusion criteria: * coagulation disorder * abnormal pre-operative levels of aptt, pt and/or thrombocytes * homologous blood transfusion last 4 weeks * coagulation disorder * use of anticoagulation medication * use of any iron supplements or erythropoietin at time of operation or during 1 week prior to operation * primary bone tumor or metastatic bone disease * unable or unwilling to participate in follow-up * unable to give informed consent * previous infection in knee * use of corticosteroids at time of operation or during 4 weeks prior to operation * any neuromuscular disorder * active infection or osteomyelitis

Keywords: osteoarthritis knee platelet concentrate
infrared ray heat treatment in liver cirrhosis patients with refractory ascites

Conditions: Liver Cirrhosis; Refractory Ascites

Summary: the objective of this study is to evaluate the therapeutic efficacy of infrared ray heat treatment in hepatic area in cirrhosis patients with refractory ascites. the evaluation of the efficacy includes the ascites pressure, portal vein velocity，saag before and after the treatment. clinical symptoms were also observed simultaneously.


Eligibility criteria:
inclusion criteria: * male * aged 18\~60 years * inpatient * diagnosed with liver cirrhosis and liver stubborn ascites. exclusion criteria: * severe problems in other vital organs(e.g.the heart,renal or lungs). * combined with malignant tumour. * combined with endocrine diseases. * combined with high fever. * infected with the aids virus

Keywords: infrared ray heat treatment liver cirrhosis refractory ascites
rocklatan® evaluation

Conditions: Glaucoma

Summary: the objective of this study is to evaluate the iop-lowering effect when subjects are switched from various latanoprost-based regimens to rocklatan. subjects will stop their iop-lowering medical therapy regimen and dose with rocklatan for the duration of the study (12 weeks).

enrollment will be stratified according to subject's iop-lowering medical therapy regimen as follows: * latanoprost monotherapy (latanoprost mono) * latanoprost plus 1 additional iop-lowering agent (latanoprost +1) * latanoprost plus 2 additional iop-lowering agents (latanoprost +2) aerie pharmaceuticals was acquired by alcon research llc on november 22, 2022.

Eligibility criteria:
key inclusion criteria: * male or female subjects age 18 or older * current diagnosis of open-angle glaucoma or ocular hypertension * subject currently being treated with latanoprost alone or latanoprost plus 1 or 2 additional agents/bottles. current iop lowering regimen is stable for at least 30 days prior to baseline visit * treated iop ≥ 20 mmhg measured in the morning (before noon) at the baseline visit by goldmann applanation tonometer * best corrected snellen visual acuity of 20/100 or better in both eyes * willingness to follow protocol requirements, including signed informed consent and health information release forms, routine follow-up schedule, completing questionnaires key exclusion criteria: * have any active ocular disease other than open-angle glaucoma or ocular hypertension that would interfere with study interpretation * use of fixed dose combination agents as part of the patient's baseline iop lowering therapy regimen, if not also on latanoprost * active ocular infection/inflammation or history of uveitis * aphakic or pseudophakic patients with a torn posterior lens capsule, or with known risk factors for macular edema * any systemic disease or clinical evidence of any condition which would make the subject, in the opinion of the investigator, unsuitable for the study or could potentially confound the study results * use of topical, periorbital, intravitreal or systemic steroid within previous 3 months or expected use during the course of the study * prior participation in any investigational drug or device study within the last 30 days prior to the baseline visit. * known sensitivity or allergy to the study medication or components * females who are pregnant, nursing, or planning a pregnancy during the study * positive pregnancy test at baseline visit (women of childbearing potential only) * women of childbearing potential who are not using a medically acceptable form of birth control

Keywords: glaucoma
prevalence of h. pylori gastritis in sleeve gastrectomy specimens

Conditions: Gastritis H Pylori; Gastritis; Obesity Associated Disorder

Summary: this is a cross-sectional study looking for prevalence of h.pylori related gastritis among patients underwent sleeve gastrectomy over five year study period. the study also looks for possible association with patients's characteristics. also, compares its findings with similar regional and international studies.


Eligibility criteria:
inclusion criteria: * patients who underwent sleeve gastrectomy * surgery was performed between january 2015 and october 2019 exclusion criteria: * patients whose resected specimens were not examined histopathologically

Keywords: histopathology sleeve gastrectomy lsg gastritis h. pylori jordan middle east
color stability of e.max cad laminate veneers cemented with light cure versus dual cure amine free adhesive resin cement

Conditions: Tooth Discoloration

Summary: light curing cements used for laminate veneers may be not totally cured in certain areas, so dual cured resin cements may solve this problem yet the dual cured cements containing amines cause yellowish discoloration of the veneers after time. a new dual cured cement which is amine free is introduced so the investigators have to try it clinically using parallel groups in randomized clinical trial.


Eligibility criteria:
inclusion criteria: all subjects are required to be: * from 18-60 years old, and able to read and sign the informed consent document * physically and psychologically able to tolerate conventional restorative procedures * have no active periodontal or pulpal diseases, have teeth with good restorations * patients with teeth problems indicated for laminate veneer (e.g. discoloration, fracture not involve more than 50% enamel loss, mild malposition, ....) * willing to return for follow-up examinations and evaluation exclusion criteria: * patients in the growth stage with partially erupted teeth * patient with fractured teeth of more than 50% enamel loss * patients with poor oral hygiene and motivation * pregnant women * psychiatric problems or unrealistic expectations * lack of opposite occluding dentition in the area intended for restoration
an observational study of combination of pegylated liposomal doxorubicin and trabectedin in routine practice in patients with recurrent partial-platinum sensitive ovarian cancer

Conditions: Ovarian Cancer

Summary: this is a non-interventional, multicenter study evaluating the efficacy and safety of the combination of pegylated liposomal doxorubicin and trabectedin in routine practice in patients with recurrent partial-platinum sensitive ovarian cancer, which is held in kazakhstan.


Eligibility criteria:
inclusion criteria: * age\>18 * histologically proven epithelial ovarian cancer * ecog 0-1 * partially platinum sensitive relapsed ovarian cancer: platinum-free interval 6 -12 months * with 1-2 or more cycles on trabectedin treatment at the recommended dose of 1.1mg/m2 q3w 3hr infusion in combination of pld at 30mg/ml with appropriate pre-medication * prior treatment with 1 or more chemotherapy regimen exclusion criteria: * platinum resistant disease: pfi \< 6 months (progression within six months after first-line platinum-based chemotherapy) * unwilling or unable to have a central venous catheter * patients with hepatic impairment (patients with elevated bilirubin) * patients with renal impairment (patients with serum creatinine \>1.5 mg/dl) * patients with hematologic impairment (baseline neutrophil counts of less than 1,500 cells/mm3 and platelets count of less than 100,000 cells/mm3) * patients with serious impaired cardiac function (patients with cardiac disease and with reduction of the qrs complex) * aids-related kaposi's sarcoma * lactation or pregnancy

Keywords: ovarian cancer, trabectedin, recurrent ovarian cancer
effect of high intensity interval training in patients with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: in this study, we are aiming to systematically review the literature on the effect of hiit on ms patients as improving physical performance, cognitive function, aerobic fitness and muscle strength. this could help guide the development of standardized clinical guidelines and direct clinical decision making by the physical therapists whether to implement this type of exercises or not.

multiple sclerosis patients have considerably negative effects on the community and the national and international economy. chronic symptoms of ms such as fatigue, cognitive impairments, emotional burden and diminished physical functioning considerably affect the daily lives of people with ms and may interfere with social and quality of life factors as friendships, family relationships and occupational status. hiit has induced significant improvements in physiological conditioning in healthy and clinical populations, and might be appropriate for persons with ms. recently, several rcts have been published evaluating the effect of hiit on ms patients. consequently, this study will systematically review all these recent literature to direct the physiotherapists whether to implement this type of exercises or not.

Eligibility criteria:
inclusion criteria: * studies: english full texts of rcts only, participants: multiple sclerosis patients with age from (20-50) years old irrespectively of sex, subtype of ms, race, diagnostic criteria, community or onset of the disease, intervention: hiit, any comparator. exclusion criteria: * studies other than english full text rcts, non adults younger than 20 years and older than 50 years, populations other than multiple sclerosis.

Keywords: multiple sclerosis and high intensity interval training
the effects of modified ultrafiltration on vancomycin levels during cardiopulmonary bypass in cardiac surgery

Conditions: Infection

Summary: antibiotics are routinely used to prevent surgical wound infection. vancomycin is a widely used antibiotic for surgery in patients with an allergy to penicillin. during cardiac surgery, cardiopulmonary bypass (cpb) and modified ultrafiltration (muf) are routinely used and can lower the level of the antibiotic. the purpose of this study is to quantify the change in plasma vancomycin concentration associated with cardiopulmonary bypass and modified ultrafiltration.

subjects having cardiac surgery in which they will be on a heart-lung machine and will receive the antibiotic vancomycin, will be able to participate. up to ten blood samples testing for vancomycin concentrations will be collected in subjects administered vancomycin as prophylaxis before cardiac surgery with cardiopulmonary bypass and modified ultrafiltration. participation will be complete once the cardiac surgery has been finished.

Eligibility criteria:
inclusion criteria: * scheduled to undergo cardiac surgery with cardiopulmonary bypass and modified ultrafiltration * age greater than 18 years old * penicillin allergy or in-hospital stay greater than 24 hours * normal renal function * normal liver function * absence of clinical and laboratory signs of infection exclusion criteria: * vancomycin allergy * pregnancy * impaired renal function * impaired liver function * morbid obesity * active infections * jehovah's witness

Keywords: heart lung machine blood pump cardiac surgery cardiopulmonary bypass circulation
weaning preterm neonates from nasal continuous positive airway pressure

Conditions: Respiratory Distress Syndrome; Hyaline Membrane Disease; Preterm Infants; Premature Infants

Summary: there is little data published concerning the best approach to nasal continuous positive airway pressure (ncpap) weaning. potential complications associated with prolonged ncpap therapy include gastric distension, nasal trauma,pneumothorax,agitation and nosocomial infection. moreover, infants on ncpap may also require more intensive nursing care and the use of extra equipment. therefore, minimizing the amount of time that a patient requires cpap may be beneficial. on the other hand, removing cpap too early may lead to complications that include: increasing apnea, increased oxygen requirement, increased work of breathing, the need to re-start cpap, and intubation and mechanical ventilation. moreover, an experimental study have demonstrated an improvement in lung growth after the prolonged use of cpap. nasal cannula (nc) flows at 1-2 l/min may also generate a positive pressure in the airway of preterm infants. the use of nc flow to generate positive airway pressure would minimize many of the application issues of ncpap. however, nc systems used in neonates routinely employ gas that is inadequately warmed and humidified, limiting the use of such flows due to increased risk of nasal mucosa injury, and possibly increasing the risk for nosocomial infection. the purpose of this randomized controlled trial is to evaluate the clinical impact of two methods for weaning preterm infants from ncpap.

the objective of this study is to test the null hypothesis that in preterm infants with gestational age of 28 to 36 weeks who are stable on cpap pressure of 5 cmh2o and with oxygen concentrations (fio2) \<0.30, keeping these infants on cpap or changing them to nc flow of 1-2 l/min will not make any difference in length of hospitalization, length of respiratory support and incidence of complications.

Eligibility criteria:
inclusion criteria: * infants born greater than or equal to 28 weeks (28+0) and less than 37 weeks (36+6) gestation * cpap pressure of 5 cm h2o * fio2 requirement = or \<0.30 * clinically stable on these cpap parameters for 24 hours pre-randomization: * respiratory rate less than 60 * no significant chest recession * no apnea requiring bagging and/or * not more than 6 apneas requiring stimulation in the preceding 24 h. * average saturation \> or = 87% * satisfactory abg (ph\> 7.25, pco2 \< 60, and base deficit \< -8) exclusion criteria: * life threatening congenital anomalies * congenital cyanotic heart diseases * congenital airway or chest wall abnormalities * pulmonary hypoplasia * known or suspected to have a neuromuscular disorder * congenital neurological disorder, severe ivh (grade 3 or 4), pvl and hydrocephalus

Keywords: nasal continuous positive airway pressure nasal cannula cpap premature rds hmd nicu
a trial to investigate the relative efficacy, safety, and tolerability of octaplas lg versus octaplas sd

Conditions: Comparison of Octaplas LG and Octaplas SD

Summary: the primary objective of the study was to compare the efficacy of octaplas lg with octaplas sd in terms of recovery of coagulation factors and other haemostatic parameters. the secondary objective of the study was to compare the safety and tolerability of octaplas lg with octaplas sd in terms of haematological and clinical chemistry parameters and adverse event monitoring.


Eligibility criteria:
inclusion criteria: * capable of understanding and complying with all aspects of the protocol. * signed informed consent. * capable of understanding the plasmapheresis information sheet and sign it. * healthy male or female volunteers, age 18 years or older. * women must have negative pregnancy test (human chorionic gonadotropin \[hcg\] based assay). * women must have sufficient methods of contraception (eg, intrauterine device, oral contraception, etc). * no clinically relevant abnormalities in medical history and general physical examination. * standard health insurance. exclusion criteria: * pregnancy or lactation. * tattoos within the last 3 months. * subject was treated therapeutically with fresh frozen plasma, blood, or plasma-derived products within the last 6 months. * hypersensitivity to blood products or plasma proteins. * history of angioedema. * history of coagulation or bleeding disorder or any other known abnormality affecting coagulation, fibrinolysis, or platelet function. * any clinically significant abnormal laboratory values. * iga deficiency. * seropositivity for hepatitis b surface antigen, hepatitis c virus, or human immunodeficiency virus type 1 or type 2 antibodies. * symptoms of a clinically relevant illness within 3 weeks before the first trial day. * history of or suspected drug or alcohol abuse. * subjects currently participating in another clinical study. * any investigational medicinal product administration within the last 4 weeks.

Keywords: octaplas lg octaplas sd
influence of the biological maturation on the antrhopometric variables and sport performance in volleyball players

Conditions: Development, Adolescent; Body Weight Changes

Summary: the project consists of a cross-sectional study in which anthropometric variables, general and specific performance variables of volleyball will be measured, and the biological maturity stage will be calculated. the main objective is to establish a relationship between the biological maturation state, the anthropometric characteristics and the performance in physical fitness tests in volleyball players between 12 and 15 years of age. to do this, there will be all the clubs in the region of murcia that have federated teams in these categories.


Eligibility criteria:
inclusion criteria: * to play volleyball in a regular basis * to have between 12 and 15 years * to participate in volleiball competitions with the team exclusion criteria: * to be injured in the moment of the measurement session * to have skipped most of the training sessions the last month * to have less than a year of experience playing volleyball

Keywords: sport performance volleyball anthropometry biological maturation
a study of neurophysiologic changes in individuals with parkinson's disease

Conditions: Parkinson's Disease; Parkinsonian Syndrome

Summary: the goal of this study is to investigate neurophysiologic tests that have the potential of serving as screening tools for parkinson's disease. these neurophysiologic tests will be administered to individuals with parkinson's disease and parkinsonian syndrome and validated against a healthy control population. specifically, this study will look at changes in motor function, cognitive function, handwriting, speech, and olfactory function in individuals with parkinson's disease, individuals at risk for parkinson's disease and healthy controls.

one of the greatest challenges in parkinson's research is the identification of individuals who are at risk or have early parkinson's disease (pd) or parkinsonian syndrome (ps). subtle signs that do not meet the diagnostic criteria for pd may occur during this period. this study will evaluate a profile of neurophysiologic tests for potentially predictive signs of pd or ps in individuals with pd or ps, those who may be at risk for pd or ps and in a population of individuals without parkinsonian symptoms or any other neurologic conditions. in addition, the study will evaluate serum samples for changes in proteins or metabolites that may be indicators of early changes associated with parkinson's disease or parkinsonian syndrome. each study participant will be scheduled for a 90 minute study visit. this visit may include the following procedures: * screening for eligibility * clinical assessments * neurological evaluation * computerized cognitive testing * olfactory testing * computerized handwriting testing * speech evaluation * blood sample for biochemical and/or genetic analysis the study will be conducted at the institute for neurodegenerative disorders (ind), which is a not for profit research institute specializing in parkinson's disease research. clinical data will be collected, stored and analyzed at ind to evaluate whether there are significant differences between the performance of the parkinsonian study participants, individuals with risk factors for pd or ps, and the healthy subjects.

Eligibility criteria:
inclusion criteria: as a participant with pd or ps: * age \>21 * clinical diagnosis of pd or ps (at least two of the three cardinal symptoms: resting tremor, rigidity, bradykinesia) and a clinical response to dopaminergic therapy for healthy control: * age \>21 exclusion criteria: as a participant with pd or ps: * any other concomitant neurologic condition likely to interfere with handwriting, use of the computer, or other motor tasks tested in this study (e.g. stroke, demyelinating disease, visual loss) for healthy control: * any indication of parkinsonism on examination * any other concomitant neurologic condition likely to interfere with handwriting, use of the computer, or other motor tasks (e.g. stroke, demyelinating disease, visual loss)

Keywords: parkinson diagnosis screening